Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) PT at $7.43

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned an average recommendation of “Buy” from the nine analysts that are covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $7.43.

A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Tuesday, October 22nd. B. Riley reissued a “buy” rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. Leerink Partners started coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price for the company. Finally, Leerink Partnrs raised shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th.

Trevi Therapeutics Trading Down 3.8 %

Shares of TRVI opened at $2.75 on Wednesday. The firm has a market cap of $211.38 million, a PE ratio of -6.27 and a beta of 1.01. The firm has a fifty day simple moving average of $3.14 and a two-hundred day simple moving average of $2.91. Trevi Therapeutics has a 1-year low of $0.97 and a 1-year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter in the previous year, the company earned ($0.08) EPS. As a group, research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Insider Activity

In related news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.02, for a total value of $33,162.62. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at $644,205.26. This represents a 4.90 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 21,595 shares of company stock worth $64,886. 24.37% of the stock is currently owned by corporate insiders.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its position in Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares during the period. Price T Rowe Associates Inc. MD bought a new position in Trevi Therapeutics in the 1st quarter worth about $47,000. Intech Investment Management LLC bought a new position in Trevi Therapeutics in the 3rd quarter worth about $63,000. Hsbc Holdings PLC bought a new position in Trevi Therapeutics in the 2nd quarter worth about $61,000. Finally, SG Americas Securities LLC bought a new position in Trevi Therapeutics in the 3rd quarter worth about $78,000. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.